Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Liabilities and Shareholders Equity (2016 - 2025)

Conmed's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $2.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 0.85% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $9.3 billion, up 0.62%, while the annual FY2025 figure was $2.3 billion, 0.85% up from the prior year.
  • Liabilities and Shareholders Equity reached $2.3 billion in Q4 2025 per CNMD's latest filing, roughly flat from $2.3 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q2 2025 to a low of $1.7 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 30.67% in 2022, then dropped 1.6% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.8 billion in 2021, then soared by 30.1% to $2.3 billion in 2022, then increased by 0.11% to $2.3 billion in 2023, then increased by 0.27% to $2.3 billion in 2024, then increased by 0.85% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Liabilities and Shareholders Equity are $2.3 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.3 billion (Q2 2025).